The Drugs Controller General of India (DCGI) has issued a show cause notice to the Serum Institute of India (SII). The SII is manufacturing Oxford University’s vaccine ‘Covishield’, in collaboration with the UK’s AstraZeneca.
Regarding the show cause notice issued by the DCGI, SII said, “We are going by DCGI’s direction and so far have not been told to pause the trials. If DCGI has any safety concerns, we will follow their instructions and abide by the standard protocols.”
The UK-based pharmaceutical giant AstraZeneca paused the trials of the vaccine on 8 September after one of the recipients of the vaccine in the UK developed an “unexplained illness”. However, in India, none of the volunteers have shown any signs of health-related complications after receiving the vaccine from SII.
The relationship between gut microbes, hormones, and dietary preferences is a fascinating area of study…
AI systems like ChatGPT have been linked to environmental concerns, with reports showing their significant…
Rabi Lamichhane, RSP chief and ex-home minister, secures bail in the Swarnalakshmi Cooperative fraud case…
Metformin, the widely prescribed drug for managing type 2 diabetes, has recently gained attention for…
California wildfires leave destruction in their wake, with Stanford experts warning of the underestimated dangers…
Report of Kenya's child abduction shows around 44 percent of child has been abducted between…